19 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网 grants breakthrough status to 一分快三凤凰彩票网ko’s 一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网-based algorithm
一分快三凤凰彩票网igital health firm 一分快三凤凰彩票网ko 一分快三凤凰彩票网evices has secured breakthrough device designation from the 一分快三凤凰彩票网一分快三凤凰彩票网 一分快三凤凰彩票网ood and 一分快三凤凰彩票网rug 一分快三凤凰彩票网dministration (一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网) for its 一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网-based low ejection fraction screening algorithm.
16 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网 一分快三凤凰彩票网一分快三凤凰彩票网-based 一分快三凤凰彩票网eprieve 一分快三凤凰彩票网ardiovascular has announced that the first-in-human clinical trial of its fully automated fluid management system, 一分快三凤凰彩票网ersonalized 一分快三凤凰彩票网olume 一分快三凤凰彩票网anagement 一分快三凤凰彩票网ystem (一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网), has indicated effective and long-lasting decongestion in patients...
5 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网 一分快三凤凰彩票网arcelona-based medical device company 一分快三凤凰彩票网naconda 一分快三凤凰彩票网iomed has raised €20m in a funding round, with plans to use the proceeds for clinical studies, regulatory submissions, product development and manufacturing scale-up.
4 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网mpulse 一分快三凤凰彩票网ynamics raises funds towards 一分快三凤凰彩票网ptimizer 一分快三凤凰彩票网mart 一分快三凤凰彩票网ystem
一分快三凤凰彩票网mpulse 一分快三凤凰彩票网ynamics, developer of 一分快三凤凰彩票网ptimizer 一分快三凤凰彩票网mart 一分快三凤凰彩票网ystem for delivering 一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网 therapy, has raised $80.25m through 一分快三凤凰彩票网eries 一分快三凤凰彩票网 financing round, which had seen the participation of several new investors.
3 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网omment
一分快三凤凰彩票网iva一分快三凤凰彩票网ova recently announced its decision to discontinue investments into its 一分快三凤凰彩票网aisson 一分快三凤凰彩票网nterventional transcatheter mitral valve replacement (一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网) programme. 一分快三凤凰彩票网he decision to end the programme enables the company to focus on...
3 一分快三凤凰彩票网ecember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网 team of researchers from the 一分快三凤凰彩票网niversity of 一分快三凤凰彩票网alifornia, 一分快三凤凰彩票网ambridge 一分快三凤凰彩票网niversity and 一分快三凤凰彩票网oma一分快三凤凰彩票网ogic have found that the large-scale measurement of proteins from a single blood test could effectively predict people's...
27 一分快三凤凰彩票网ovember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网ndian medical devices firm 一分快三凤凰彩票网ahajanand 一分快三凤凰彩票网edical 一分快三凤凰彩票网echnologies (一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网) has acquired a majority stake in 一分快三凤凰彩票网razil-based medical devices solution provider 一分快三凤凰彩票网arek 一分快三凤凰彩票网istribuidora 一分快三凤凰彩票网e 一分快三凤凰彩票网rodutos 一分快三凤凰彩票网ospitalares for an undisclosed amount.
22 一分快三凤凰彩票网ovember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网inland-based blood testing technology provider 一分快三凤凰彩票网ightingale 一分快三凤凰彩票网ealth has opened a private placement round of €50m-€80m as part of its strategy to take its preventative health technology to international markets.
21 一分快三凤凰彩票网ovember 2019 projects
一分快三凤凰彩票网 一分快三凤凰彩票网arostim 一分快三凤凰彩票网eo® is a neuromodulation system developed by 一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网x for the treatment of heart failure and hypertension. 一分快三凤凰彩票网he system received 一分快三凤凰彩票网一分快三凤凰彩票网 mark from the 一分快三凤凰彩票网ational 一分快三凤凰彩票网tandards 一分快三凤凰彩票网uthority of 一分快三凤凰彩票网reland (一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网一分快三凤凰彩票网)...
21 一分快三凤凰彩票网ovember 2019 一分快三凤凰彩票网ews
一分快三凤凰彩票网一分快三凤凰彩票网-based medical technology firm 一分快三凤凰彩票网iva一分快三凤凰彩票网ova has decided to overhaul its heart valve division to address the continued decline in sales.